The inhibitory effect of apigenin on the agonist-induced regulation of vascular contractility via calcium desensitization-related pathways

Hyun Dong Je1†, Hyeong-Dong Kim1† and Hyen-Oh La3*  
1Department of Pharmacology, College of Pharmacy, Catholic University of Daegu, Gyeongbuk 712-702,  
2Department of Physical Therapy, College of Health Science, Korea University, Seoul 336-871,  
3Department of Pharmacology, College of Medicine, The Catholic University of Korea, Seoul 137-701, Republic of Korea

Abstract
Apigenin, a natural flavonoid found in a variety of vegetables and fruits, has been shown to possess many biological functions. The present study was undertaken to investigate the influence of apigenin on vascular smooth muscle contractility and to determine the mechanism involved. Denuded aortic rings from male rats were used and isometric contractions were recorded and combined with molecular experiments. Apigenin significantly relaxed fluoride-, thromboxane A2 mimetic- or phorbol ester-induced vascular contraction, which suggests that apigenin could be an anti-hypertensive that reduces agonist-induced vascular contraction regardless of endothelial nitric oxide synthesis. Furthermore, apigenin significantly inhibited fluoride-induced increases in pMYPT1 levels and phorbol ester-induced increases in pERK1/2 levels, which suggests the mechanism involving the inhibition of Rho-kinase and MEK activity and the subsequent phosphorylation of MYPT1 and ERK1/2. This study provides evidence regarding the mechanism underlying the relaxation effect of apigenin on agonist-induced vascular contraction regardless of endothelial function.

Key Words: Apigenin, ERK1/2, Fluoride, MYPT1, Phorbol ester, Rho-kinase

INTRODUCTION
Apigenin (4',5,7-trihydroxyflavone, Fig. 1) is a natural flavonoid that is found abundantly in parsley, peppermint, lemon, perilla, berries, and fruits (Peterson and Dwyer, 1998). Apigenin has been reported to have beneficial effects which include anti-inflammatory (Nicholas et al., 2007) and anti-carcinogenic effects for skin, and free radical scavenging properties in many in vitro systems (Han et al., 2012). Studies on anti-carcinogenic effects have shown that apigenin possesses growth inhibitory properties against many human cancer cell lines, for examples, breast, colon (Wang et al., 2000), skin (Caltagirone et al., 2000), thyroid, leukemia cells, and solid malignant tumor cells (Fotsis et al., 1998). Although the influence of endothelial nitric oxide synthesis is well established, we investigated the possible influence and related mechanisms of the anti-inflammatory apigenin on vascular smooth muscle contractility to develop a better antihypertensive. Denuded aortic rings from male Sprague-Dawley rats were used and isometric contractions were recorded using a computerized data acquisition system and combined with molecular experiments. Alterations in the arterial tone are frequently associated with cardiovascular diseases constituting an important cause of morbidity and mortality in humans, one of which is hypertension that is a multifactorial disorder that involves many mechanisms including endothelial dysfunction and leading to risk factors for cardiovascular diseases. Besides endothelial dysfunction, it is generally accepted that vascular smooth muscle contractility is predominantly controlled by Ca2+ sig-

Fig. 1. The chemical structure of apigenin (4',5,7-trihydroxyflavone).
naling involving Ca\textsuperscript{2+} influx, release or sensitization and regulating a Ca\textsuperscript{2+}-dependent increase in the phosphorylation of a 20 kDa myosin light chain (MLC\textsubscript{20}) (Somlyo and Somlyo, 1994). The extent of MLC\textsubscript{20} phosphorylation or force of contraction induced by agonist stimulation is usually higher than that caused by an increase in the cytosolic Ca\textsuperscript{2+} concentration referred to as Ca\textsuperscript{2+} sensitization (Somlyo and Somlyo, 1994). Subsequent studies suggested that the inhibition of MLC phosphatase by Rho-kinase (Kitazawa et al., 1991; Uehata et al., 1997; Somlyo and Somlyo, 1998; Sakurada et al., 2003) or thin filament regulation including the activation of protein kinase C (PKC), mitogen-activated protein kinase kinases (MEK) and extracellular signal regulated kinase (ERK) 1/2, and phosphorylation of the actin binding protein caldesmon (Wier and Morgan, 2003) may be major components of the pathway that facilitates in Ca\textsuperscript{2+} sensitization.

Activation of ERK1/2 cannot only regulate vascular contractility but also is connected with pathologic hypertrophy, hyperplasia, hypertension and atherosclerosis (Xu et al., 1996; Touyz et al., 1999). ERK1/2 is activated by threonine and tyrosine phosphorylation by the specific kinase MEK activated by Raf. In various smooth muscles, fluoride, phorbol ester or thromboxane A\textsubscript{2} mimetic has been shown to induce contractions, which may be due to primarily enhanced Ca\textsuperscript{2+} sensitivity or partially increased Ca\textsuperscript{2+} concentration only in thromboxane A\textsubscript{2} mimetic. ERK1/2 activation was induced by the phorbol ester, phorbol 12,13-dibutyrate (PDBu). The stimulus PDBu triggers ERK1/2 dependent cytoskeletal remodeling and formation of podosomes inducing ERK1/2 activation (Gu et al., 2007). On the other hand, it is possible that the contractions induced by fluoride or thromboxane A\textsubscript{2} mimetic involve the RhoA/Rho-kinase pathway (Jeon et al., 2006). However, it has not been reported as to whether this pathway is inhibited during apigenin-induced vascular smooth muscle relaxation in aortic rings precontracted with Rho-kinase activator fluoride or MEK activator phorbol ester. Therefore, the aim of the present study was to investigate the possible roles of Rho-kinase or MEK inhibition on Ca\textsuperscript{2+} desensitization during the apigenin-induced relaxation of isolated rat aortas by using RhoA/Rho-kinase activators fluoride or thromboxane A\textsubscript{2} mimetic or a MEK activator phorbol ester excluding endothelial nitric oxide synthesis.

**MATERIALS AND METHODS**

**Tissue preparation**

Male Sprague-Dawley rats weighing 200-300 g were anesthetized with sodium pentobarbital (50 mg/kg i.p.) as subjected to cervical dislocation, in accord with the procedures approved by the Institutional Animal Care and Use Committee at our institutions. Thoracic aortas were quickly removed and immersed in oxygenated (95% O\textsubscript{2}/5% CO\textsubscript{2}) physiological saline solution composed of (mM): 115.0 NaCl, 4.7 KCl, 2.5 CaCl\textsubscript{2}, 1.2 MgCl\textsubscript{2}, 25.0 NaHCO\textsubscript{3}, 1.2 KH\textsubscript{2}PO\textsubscript{4}, and 10.0 dextrose (pH 7.4). They were then freed of adherent connective tissue, and aortic endothelia were removed by gentle abrasion using a cell scraper.

**Contraction measurements**

Two stainless-steel triangles were inserted through each vessel ring and each aortic ring was then suspended in a water-jacketed organ bath (10 ml) maintained at 37°C and aerated with a mixture of 95% O\textsubscript{2} and 5% CO\textsubscript{2}. One triangle was anchored to a stationary support, and the other was connected to an isometric force transducer (Grass FT03C, Quincy, Mass., USA). The rings were stretched passively by applying an optimal resting tension of 2.0 g, which was maintained throughout the experiment. Each ring was equilibrated in the organ bath solution for 60 min before contractile responses to 50 mM KCl were measured. Isometric contractions were recorded using a computerized data acquisition system (PowerLab/8SP, AD Instruments, Castle Hill, NSW, Australia).

The direct effect of apigenin was determined by addition of it after KCl (50 mM), thromboxane A\textsubscript{2} mimetic (U46619, 0.1 \textmu M), phorbol ester (1 \textmu M) or fluoride (6 mM) induced contractions had plateaued in normal Krebs’ solution.

**Western blot analysis**

Muscle strips were quick-frozen by immersion in a dry ice/acetone slurry containing 10% trichloroacetic acid (TCA) and 10 mM dithiothreitol (DTT). Muscles were stored at -80°C until use. Tissues were brought up to room temperature in a dry ice/acetone/TCA/DTT mixture and then homogenized in a buffer containing 20 mM MOPS, 4% SDS, 10% glycerol, 10 mM DTT, 20 mM β-glycerophosphate, 5.5 μM leupeptin, 5.5 μM pepstatin, 20 kIU aprotinin, 2 mM Na\textsubscript{3}VO\textsubscript{4}, 1 mM NaF, 100 mM Zn\textsubscript{Cl}\textsubscript{2}, 20 μM 4-(2-aminoethyl)benzenesulphonyl fluoride (AEBSF) and 5 mM EGTA. Protein-matched samples (modified Lowry protein assay, DC Protein Assay Kit, Bio-Rad) were electrophoresed on sodium dodecyl sulfate polyacrylamide gel electrophoresis SDS-PAGE (Protogel, National Diagnostics), transferred to polyvinylidene fluoride PVDF membranes, and subjected to immunostaining and densitometry using appropriate antibodies. The success of protein matching was confirmed by Naphthol Blue Black staining of the membrane and by densitometry of the actin band. Lane loading variations were corrected by normalization versus β-actin.

**MLC\textsubscript{20} Phosphorylation**

Muscle strips were quick-frozen by immersion in aceton containing 10% TCA and 10 mM DTT precooled to -80°C. Tissues were brought to room temperature in aceton/TCA/DTT, then ground with glass pestles, and washed with ether to remove TCA. Tissues were extracted in a urea sample buffer as previously described and run on 10% polyacrylamide gels. Proteins were transferred to PVDF membranes and subjected to immunoblot with a specific MLC\textsubscript{20} antibody (1:1500, Sigma). Anti-mouse IgG (Goat) conjugated with horseradish peroxidase was used as a secondary antibody (1:2000, Upstate). Bands were detected with enhanced chemiluminescence (ECL) visualized on films and then analyzed by a molecular imager.

**Chemicals and antibodies**

Drugs and chemicals were obtained from the following sources. Sodium fluoride, KCl, acetylcholine, apigenin, U46619 and phorbol 12,13-dibutyrate were purchased from Sigma (St. Louis, MO, USA). DTT, TCA and acetone were obtained from Fisher Scientific (Hampton, NH, USA). Enhanced chemiluminescence (ECL) kits were from Pierce (Rockford, IL, USA). Antibodies against phospho-myosin phosphatase targeting subunit protein 1 (phospho-MYPT1) at Thr855 (1:5,000), MYPT1, ERK or phosphoERK at Thr202/Tyr204 were purchased from Je et al.  Mechanisms Involved in the Effect of Apigenin
Cell Signaling Technology (Danvers, MA, USA) or Upstate Biotechnology (Lake Placid, NY, USA) to determine levels of RhoA/Rho-kinase activity (Wilson et al., 2005; Wooldridge et al., 2004) or MEK activity. Anti-mouse IgM (goat) and anti-rabbit IgG (goat), conjugated with horseradish peroxidase, were used as secondary antibodies (1:2,000 and 1:2,000, respectively, Upstate, Lake Placid, NY). Apigenin was prepared in dimethyl sulfoxide (DMSO) as a 100 mM stock solution and frozen at -20°C for later use. DMSO alone had no observable effect at concentrations used (data not shown).

Statistics
The data were expressed as mean ± standard error of the mean (SEM). The student’s unpaired t test or ANOVA was used to determine the statistical significance of the means between two groups using SPSS 12.0 (SPSS Inc., Chicago, Illinois, USA). p values <0.05 were regarded as statistically significant.

RESULTS
Effect of apigenin on contractions of endothelium-denud ed aortas induced by a full RhoA/Rho-kinase activator fluoride or thromboxane A₂ mimetic
Endothelium was removed by gentle abrasion with a cell scraper to identify the direct effect of apigenin on vascular smooth muscle. The absence of endothelium was confirmed by a lack of relaxation after treating precontracted ring segments with acetylcholine (1 µM). Apigenin showed no significant effect on basal tension (data not shown), and significantly inhibited the contraction induced by a Rho-kinase activator fluoride regardless of endothelial nitric oxide synthesis (Fig. 2). This suggests that the relaxation mechanism of apigenin might involve the inhibition of Rho-kinase activity in addition to endothelial nitric oxide synthesis and the subsequent activation of guanylyl cyclase. On the other hand, apigenin at the same concentration significantly inhibited thromboxane A₂ mimetic U46619-induced contraction in denuded muscles (Fig. 3) suggesting that thromboxane A₂ mimetic acts similarly with fluoride where Rho-kinase activation was the main pathway.

Effect of apigenin on the contractions of denuded aortas induced by a MEK activator phorbol ester
Phorbol esters used have been proved to be MEK activators and partial RhoA/Rho-kinase activators (data not shown). Interestingly, phorbol 12,13-dibutyrate-induced contraction was significantly inhibited by apigenin at a low concentration regardless of endothelial nitric oxide synthesis (Fig. 4), which suggested that thin or actin filament regulation including MEK/ERK activation were significantly inhibited.

Effect of apigenin on levels of ERK1/2 phosphorylation at Thr-202/Tyr-204
To confirm the role of apigenin on thin filament regulation of smooth muscle contractility, we measured levels of ERK1/2 and phospho-ERK1/2 in muscles quick frozen after 60 minutes of exposure to apigenin for the equilibration. Each relaxing ring was precontracted with 1 µM phorbol ester (phorbol 12,13-dibutyrate). As compared with vehicle-treated rat aortas,
a significant decrease in ERK 1/2 phosphorylation at Thr202/Tyr204 was led by apigenin in these apigenin (0.1 mM)-treated rat aortas in the absence of endothelium compared to vehicle-treated rat aortas showing full vasorelaxation (Fig. 4) and thin filament regulation. These findings show that thin or actin filament regulation including ERK1/2 phosphorylation via MEK activation might be of importance in the decreased contractility induced by apigenin.

**DISCUSSION**

The present study demonstrates that apigenin can modulate the vascular contractility in an agonist-dependent manner. Interestingly, the mechanism involved seems to be not...
only endothelium-dependent but also to involve the nonspecific inhibition of MEK and Rho-kinase activity. Apigenin has been previously recognized for its anti-inflammatory, antioxidant activity or endothelial vasorelaxation (Zhang et al., 2000). Therefore, we investigated whether the inhibition of RhoA/Rho-kinase or MEK activity contributes to apigenin-induced vascular relaxation in rat aortas denuded and precontracted by a RhoA/Rho-kinase activator fluoride or by a MEK activator phorbol ester.

The mechanism by which phorbol ester activates MEK/ERK has been established (Kordowska et al., 2006; Gu et al., 2007). On the other hand, previous studies that examined the mechanisms underlying arterial contractions induced by fluoride or thromboxane A₂ mimetic have reported variable findings with regard to the contraction triggered by calcium entry and Rho-kinase activation (Wilson et al., 2005; Tsai and Jiang, 2006). These findings are consistent with the notion that apigenin can decrease phorbol ester or fluoride-induced contraction by inhibiting MEK or Rho-kinase activity.

The mechanisms by which MEK activation causes vascular contraction is an area of intense study, and several possibilities exist. The phosphorylation of caldesmon by MEK/ERK appears to regulate smooth muscle contractility (Kordowska et al., 2006). In this process MEK/ERK is activated by PKC which in turn can be stimulated by phorbol esters or GPCR receptor agonists.

The present study demonstrates that apigenin ameliorates the maximal or submaximal contraction induced by vasoconstrictor fluoride or phorbol ester endothelium-independently (Fig. 2, 4), and that this ameliorative mechanism involves the MEK/ERK and RhoA/Rho-kinase pathway. Previously, most vasodilation was believed to be caused by endothelial nitric oxide synthesis and the subsequent activation of guanylyl cyclase (Zhang et al., 2000). Zhang et al. reported apigenin-induced endothelium-dependent relaxation and related pathway involving cGMP production. In the present study, apigenin at a low concentration significantly inhibited phorbol ester-or fluoride-induced contraction regardless of endothelial function (Fig. 2, 4). Furthermore, apigenin decreased phosphorylation of extracellular signal-regulated kinase (ERK) 1/2 induced by phorbol ester (Fig. 5) and significantly decreased the phosphorylation of MYPT1 at Thr855 induced by fluoride (Fig. 6) with full relaxation (Fig. 2) suggesting the inhibition of Rho-kinase or MEK activity as a major mechanism.

MLC₂₀ is known to be phosphorylated by both MLCK and Rho-kinase (Somlyo and Somlyo, 1994). The activation of Rho-kinase by U46619 or fluoride inhibits the activity of myosin light chain phosphatase through the phosphorylation of MYPT1, leading to an increased MLC₂₀ phosphorylation as well as contractions (Sakurada et al., 2003; Wilson et al., 2005). Coincidentally, fluoride phosphorylated MLC₂₀ which was inhibited by apigenin (Fig. 7).

In summary, apigenin significantly attenuates the contractions induced by a MEK activator phorbol ester regardless of endothelial function. Furthermore, a Rho-kinase activator fluoride-induced contraction was significantly inhibited by apigenin at this low concentration. Thus, the mechanism underlying the relaxation induced by apigenin in phorbol ester or fluoride-induced contractions involves the nonspecific inhibition of MEK activity and Rho-kinase activity. Interestingly, during fluoride-induced contraction, the inhibition of Rho-kinase activity and subsequent MYPT1 phosphorylation induced by apigenin suggest that Rho-kinase inactivation is required for relaxation. In conclusion, in addition to endothelial nitric oxide synthesis (Zhang et al., 2000), both MEK and Rho-kinase inhibition make a major contribution to the mechanism responsible for apigenin-induced vasorelaxation in the denuded muscle and the decrease of intracellular calcium level which should be elucidated directly may be involved as well (Rondono et al., 2009).

REFERENCES
Caltagirone, S., Rossi, C., Poggi, A., Ranelletti, F. O., Natali, P. G., Brunetti, M., Aiello, F. B. and Piantelli, M. (2000) Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. Int. J. Cancer 87, 595-600.

Fotsis, T., Pepper, M. S., Montesano, R., Aktas, E., Breit, S., Schweiger, L., Rasku, S., Wahala, K. and Adlercreutz, H. (1998) Phytoestrogens and inhibition of angiogenesis. Baillieres Clin. Endocrinol. Metab. 12, 649-666.

Gu, Z., Kordowska, J., Williams, G. L., Wang, C. L. and Hai, C. M. (2007) Erk1/2 MAPK and caldesmon differentially regulate podesome dynamics in A7r5 vascular smooth muscle cells. Exp. Cell Res. 313, 849-866.

Han, J. Y., Ahn, S. Y., Kim, C. S., Yoo, S. K., Kim, S. K., Kim, H. C., Hong, J. T. and Oh, K. W. (2012) Protection of apigenin against kainate-induced excitotoxicity by anti-oxidative effects. Biol. Pharm. Bull. 35, 1440-1446.

Jeon, S. B., Jin, F., Kim, J. I., Kim, S. H., Suk, K., Chae, S. C., Jun, J. E., Park, W. H. and Kim, I. K. (2006) A role for Rho kinase in vascular contraction evoked by sodium fluoride. Biochem. Biophys. Res. Commun. 343, 27-33.

Kitzazawa, T., Masuo, M. and Somlyo, A. P. (1991) G-protein-mediated inhibition of myosin light-chain phosphatase in vascular smooth muscle. Proc. Natl. Acad. Sci. U.S.A. 88, 9307-9310.

Kordowska, J., Huang, R. and Wang, C. L. (2006) Phosphorylation of caldesmon during smooth muscle contraction and cell migration or proliferation. J. Biomed. Sci. 13, 159-172.

Nicholas, C., Batra, S., Vargo, M. A., Voss, O. H., Gavriliu, M. A., Wewers, M. D., Guttridge, D. C., Grotewold, E. and Dooseff, A. I. (2007) Apigenin blocks lipopolysaccharide-induced lethality in vivo and proinflammatory cytokines expression by inactivating NF-κB through the suppression of p65 phosphorylation. J. Immunol. 179, 7121-7127.

Peterson, J. and Dwyer, J. (1988) Flavonoids: dietary occurrence and biochemical activity. Nutr. Res. 18, 1995-2018.

Rondono, A., Serio, R. and Mulé, F. (2009) Gastric relaxation induced by apigenin and quercetin: analysis of the mechanism of action. Life Sci. 85, 85-90.

Sakurada, S., Takuwa, N., Sugimoto, N., Wang, Y., Seto, M., Sasaki, Y. and Takuwa, Y. (2003) Ca²⁺-dependent activation of Rho and Rho-kinase in membrane depolarization-induced and receptor stimulation-induced vascular smooth muscle contraction. Circ. Res. 93, 548-556.

Somlyo, A. P. and Somlyo, A. V. (1994) Signal transduction and regulation in smooth muscle. Nature 372, 231-236.

Somlyo, A. P. and Somlyo, A. V. (1998) From pharmacomechanical coupling to G-proteins and myosin phosphatase. Acta Physiol. Scand. 164, 437-448.

Touyz, R. M., Deng, L. Y., He, G., Wu, X. H. and Schiffin, E. L. (1999) Angiotensin II stimulates DNA and protein synthesis in vascular smooth muscle cells from human arteries: role of extracellular signal-regulated kinases. J. Hypertens. 17, 907-916.

Tsai, M. H. and Jiang, M. J. (2006) Rho-kinase-mediated regulation of receptor-agonist-stimulated smooth muscle contraction. Pflugers Arch. 453, 223-232.

Uehata, M., Ishizaki, T., Sato, H., Ono, T., Kawahara, T., Morishita, T., Tamakawa, H., Yamagami, K., Inui, J., Maekawa, M. and Narumiya, S. (1997) Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389,
Je et al. Mechanisms Involved in the Effect of Apigenin

990-994.
Wang, W., Heideman, L., Chung, C. S., Pelling, J. C., Koehler, K. J. and Birt, D. F. (2000) Cell-cycle arrest at G2/M and growth inhibition by apigenin in human colon carcinoma cell lines. Mol. Carcinog. 28, 102-110.

Wier, W. G. and Morgan, K. G. (2003) α1-Adrenergic signaling mechanisms in contraction of resistance arteries. Rev. Physiol. Biochem. Pharmacol. 150, 91-139.

Wilson, D. P., Susnjar, M., Kiss, E., Sutherland, C. and Walsh, M. P. (2005) Thromboxane A2-induced contraction of rat caudal arterial smooth muscle involves activation of Ca2+ entry and Ca2+ sensitization: Rho-associated kinase-mediated phosphorylation of MYPT1 at Thr-855, but not Thr-697. Biochem. J. 389, 763-774.

Wooldridge, A. A., MacDonald, J. A., Erdodi, F., Ma, C., Borman, M. A., Hartshorne, D. J., and Haystead, T. A. (2004) Smooth muscle phosphatase is regulated in vivo by exclusion of phosphorylation of threonine 696 of MYPT1 by phosphorylation of Serine 695 in response to cyclic nucleotides. J. Biol. Chem. 279, 34496-34504.

Xu, Q., Liu, Y., Gorospe, M., Udelsman, R. and Holbrook, N. J. (1996) Acute hypertension activates mitogen-activated protein kinases in arterial wall. J. Clin. Invest. 97, 508-514.

Zhang, Y. H., Park, Y. S., Kim, T. J., Fang, L. H., Ahn, H. Y., Hong, J. T., Kim, Y., Lee, C. K. and Yun, Y. P. (2000) Endothelium-dependent vasorelaxant and antiproliferative effects of apigenin. Gen. Pharmacol. 35, 341-347.